Skip to main content
Tianjin Ringpu Bio-Technology Co.,Ltd. logo

Tianjin Ringpu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 300119 ISIN · CNE100000TV1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,284 across all filing types
Latest filing 2025-02-05 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 300119

About Tianjin Ringpu Bio-Technology Co.,Ltd.

https://www.ringpu.com

Tianjin Ringpu Bio-Technology Co.,Ltd. is a high-tech enterprise specializing in the research, development, production, and sale of animal health products. The company offers a comprehensive portfolio that includes veterinary biological products, chemical drugs, feed additives, and pet health solutions. Its product range covers vaccines for poultry and livestock, as well as various pharmaceutical formulations such as injections, powders, and oral solutions. Ringpu Bio-Technology emphasizes innovation through its dedicated R&D centers, focusing on disease prevention and treatment to support the global animal husbandry industry. The company provides integrated health management services and high-quality veterinary medicines to ensure food safety and animal welfare.

Recent filings

Filing Released Lang Actions
关于回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from 瑞普生物股份有限公司 regarding the progress of its share repurchase program. It details the number of shares repurchased, the price range, total amount spent, and compliance with regulatory requirements. The document does not contain full financial statements or comprehensive financial analysis but focuses on the update of the company's buyback activity. The document length is 1497 characters, which is relatively short and consistent with a progress update rather than a full report. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback or sale of its own shares.
2025-02-05 Chinese
关于部分募集资金投资项目结项及部分募集资金补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the completion (结项) of certain fundraising investment projects and the supplementary use of some of the raised funds as working capital. It details the amounts raised, the use of funds, surplus funds, and the approval process by the board and supervisory committee. It references regulatory guidelines on fundraising management and states that the matter will be submitted to the shareholders' meeting for approval. The document is not a full financial report but an update on capital usage and project status related to fundraising. It is also relatively short (4246 characters) and serves as a formal announcement rather than a detailed financial report or audit. Therefore, it fits best under Capital/Financing Update (CAP).
2025-01-27 Chinese
第五届董事会第二十一次（临时）会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board of directors meeting of 瑞普生物股份有限公司. It details the meeting date, attendance, agenda items discussed, voting results, and mentions that some resolutions require shareholder approval at an upcoming extraordinary general meeting. The content focuses on board decisions regarding fundraising project closure, related party transactions, and scheduling a shareholders meeting. There are no financial statements, audit opinions, or detailed financial data presented. The document is a corporate governance announcement about board meeting resolutions rather than a full management report or financial filing. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management.
2025-01-27 Chinese
关于预计2025年度日常关联交易事项的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 瑞普生物股份有限公司 regarding the expected daily related party transactions for the fiscal year 2025. It includes detailed descriptions of the types of transactions, estimated amounts, related parties, and approvals by the board and independent directors. The document is a formal disclosure of anticipated related party transactions, which is a regulatory announcement rather than a financial report or management discussion. It does not contain financial statements or detailed financial analysis, nor is it a report of voting results or a management change. The document is regulatory in nature, providing compliance information about related party transactions as required by stock exchange rules. Therefore, it fits best under Regulatory Filings (RNS).
2025-01-27 Chinese
中国银河证券股份有限公司关于瑞普生物股份有限公司部分募集资金投资项目结项及部分募集资金补充流动资金的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from China Galaxy Securities regarding the completion and supplementary use of certain raised funds by Ruipu Bio Co., Ltd. It references regulatory approvals, specific fundraising projects, amounts, and the use of funds, including board and supervisory committee approvals. The document is focused on the verification and audit of the use of raised funds, not the full annual report or interim financial statements. It is a formal audit-related opinion on fundraising and fund usage compliance, consistent with an Audit Report / Information filing. The document length is 4020 characters, which is substantive and contains detailed financial and regulatory information, not merely an announcement or certification. Therefore, the appropriate classification is AR (Audit Report / Information). Q1 2025
2025-01-27 Chinese
关于召开2025年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a detailed notice about convening the 2025 first extraordinary general meeting of shareholders for 瑞普生物股份有限公司. It includes information about the meeting date, voting procedures (both onsite and online), agenda items to be discussed and voted on, registration details, and proxy voting instructions. There is no financial data, earnings information, or audit content. The document is not a report itself but a formal announcement and invitation to shareholders to attend and vote at the meeting. It fits the definition of a Proxy Solicitation & Information Statement (PSI), which are materials sent to shareholders to provide information and request votes for meetings.
2025-01-27 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.